Notification

February 2016: SMC decisions

The Scottish Medicines Consortium has approved the following medicines for use in NHS Scotland for specific indications: fulvestrant (Faslodex; AstraZeneca); golimumab (Simponi; Merck Sharp and Dohme); guanfacine (Intuniv; Shire); panobinostat (Farydak; Novartis); and ulipristal acetate (Esmya; Gedeon Richter). 

Eculizumab (Soliris; Alexion), pixantrone (Pixuvri; CTI Life Sciences) and teduglutide (Revestive; NPS Pharma) have not been recommended for use.

Citation: The Salvadore DOI: 10.1211/PJ.2016.20200782

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.

    £33.00
  • Stockley's Drug Interactions Pocket Companion

    The 2016 pocket guide to drug interactions and their management, for the busy healthcare professional.

    £31.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

вимакс форте купить в украине

недорогие препараты для повышения потенции у мужчин

Cialis sans ordonnance